Theodore R Schroeder
CIK 1378690 · Chief Executive Officer · last filed 2026-05-21
Theodore R Schroeder is a Chief Executive Officer who has filed 122 SEC Form 4 insider transactions across 9 companies since 2007. The most recent filing, for PHAT, was dated May 21, 2026. Across all open-market trades the lifetime net is −$1.4M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $871.1K across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$871.1K
9
122
-$1.41M
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| PHAT | Director | 45,122 | $10.37 | $467.9K | $0 | 2 | 2026-05-21 |
| Cidara Therapeutics, Inc. (CDTX) Delisted | Director | — | $221.38 | — | $0 | 13 | 2026-01-07 |
| Nabriva Therapeutics plc (NBRV) Delisted | Chief Executive Officer | 129,478 | $1.42 | $183.9K | $203.3K | 68 | 2023-01-31 |
| OTONOMY, INC. (OTIC) Delisted | Director | — | $0.08 | — | $0 | 8 | 2022-06-23 |
| COLL | Director | 11,007 | $34.64 | $381.3K | $0 | 2 | 2020-05-22 |
| ESPR | Director | 6,960 | $3.15 | $21.9K | $0 | 4 | 2019-04-29 |
| HYPERION THERAPEUTICS INC (HPTX) Delisted | Director | 0 | — | — | $0 | 2 | 2015-05-08 |
| CADENCE PHARMACEUTICALS INC (CADX) Delisted | President, CEO | 320,164 | — | — | -$1.61M | 17 | 2014-02-12 |
| Trius Therapeutics Inc (TSRX) Delisted | Director | — | — | — | $0 | 4 | 2013-05-23 |
Recent Filings
122 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-05-21 | PHAT | Grant (A) | +24,122 | $0 | EDGAR |
| 2026-01-07 | Cidara Therapeutics, Inc. (CDTX) Delisted | Disp (D) | — | $0 | EDGAR |
| 2025-06-18 | Cidara Therapeutics, Inc. (CDTX) Delisted | Grant (A) | — | $0 | EDGAR |
| 2025-04-16 | PHAT | Grant (A) | +21,000 | $0 | EDGAR |
| 2024-12-19 | Cidara Therapeutics, Inc. (CDTX) Delisted | Grant (A) | — | $0 | EDGAR |
| 2024-07-19 | Cidara Therapeutics, Inc. (CDTX) Delisted | Grant (A) | — | $0 | EDGAR |
| 2023-06-23 | Cidara Therapeutics, Inc. (CDTX) Delisted | Grant (A) | — | $0 | EDGAR |
| 2023-01-31 | Nabriva Therapeutics plc (NBRV) Delisted | Tax (F) | −431 | -$646 | EDGAR |
| 2023-01-10 | Nabriva Therapeutics plc (NBRV) Delisted | Tax (F) | −11 | -$14 | EDGAR |
| 2023-01-04 | Nabriva Therapeutics plc (NBRV) Delisted | Tax (F) | −5 | -$9 | EDGAR |